Eosinophil-derived neutralizing agent
Alternative Names: EDNA; Eosinophil-derived neurotoxinLatest Information Update: 26 Apr 2002
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Ribonuclease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 10 Jan 2000 Eosinophil-derived neutralizing agent is available for licensing (http://www.nih.gov/od/ott/EDNA.htm)
- 02 Nov 1999 New profile
- 02 Nov 1999 Preclinical development for Parainfluenza virus infections in USA (Inhalation)